Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INMT | O95050 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 5/20 | 0.41 |
| ▸ | MME | P08473 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 2/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 7/20 | 0.38 |
| ▸ | MMP3 | P08254 | 7/20 | 0.38 |
| ▸ | NPY1R | P25929 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL318738 | 1.00 | INMT (0.42) | INMTGAAL3MBTL1ACEMME | |
| SCHEMBL21143944 | 0.95 | ACE (0.44) | GAAL3MBTL1ACEMMEF10 | |
| SCHEMBL5638958 | 0.95 | ACE (0.44) | GAAL3MBTL1ACEMMEF10 | |
| SCHEMBL13464988 | 0.84 | MMP1 (0.43) | INMTGAAL3MBTL1ACEMME | |
| SCHEMBL318215 | 0.81 | MMP1 (0.53) | ACEMMEMMP1MMP3SRC | |
| SCHEMBL319693 | 0.80 | F2 (0.56) | GAAL3MBTL1F10MMP1MMP3 | |
| SCHEMBL319691 | 0.80 | F2 (0.56) | GAAL3MBTL1F10MMP1MMP3 | |
| SCHEMBL10560930 | 0.80 | GAA (0.36) | INMTGAAL3MBTL1ACE | |
| SCHEMBL10560918 | 0.80 | GAA (0.36) | INMTGAAL3MBTL1ACE | |
| SCHEMBL10941726 | 0.79 | ACE (0.59) | ACEMMEF10MMP1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130190289-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-25 | — | — | US | disclosed |
| EP-2585447-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | Vertex Pharmaceuticals Incorporated (US) | 2013-05-01 | — | — | EP | disclosed |
| WO-2012006055-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190289-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | SLC10A1, ACE, CEL | INMT 1469/4885GAA 64/4885L3MBTL1 3591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.